The Genetics of Dilated Cardiomyopathy: A Quebec-Based Study

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2008 by McGill University Health Center.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
McGill University Health Center
ClinicalTrials.gov Identifier:
NCT00523653
First received: August 29, 2007
Last updated: March 17, 2008
Last verified: March 2008
  Purpose

Dilated cardiomyopathy (DCM) affects about 200,000 Canadians. Eighty percent of these cases are of unclear cause, often occuring in families. We believe that mutations in specific already-identified genes contribute to DCM in Quebec and that certain mutations may account for a significant proportion of cases due to the well-documented "founder effect". Two hundred patients with DCM followed in our Heart Function Clinic will be approached for one blood sample at their routine clinic visit to test this hypothesis. The samples will be tested in the Laboratory of Cardiovascular Genetics at the Royal Victoria Hospital.


Condition Intervention
Dilated Cardiomyopathy (DCM)
Other: blood test

Study Type: Observational
Study Design: Observational Model: Family-Based
Time Perspective: Prospective

Resource links provided by NLM:


Further study details as provided by McGill University Health Center:

Estimated Enrollment: 200
Study Start Date: January 2008
Estimated Study Completion Date: December 2008
Intervention Details:
    Other: blood test
    looking at DNA
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Patients with Dilated cardiomyopathy followed at the Heart Function Clinic and their families

Criteria

Inclusion Criteria:

  • Followed at MUHC Heart Function Centre
  • Documented EF of less than or equal to 35% and an enlarged heart with a left ventricular end-diastolic size of greater than 6 cm.
  • Patient's written consent

Exclusion Criteria:

  • Patients with a known underlying condition that results in a weakened and enlarged heart
  • Patients unable to read and understand the consent form
  • Patients who do not wish to participate
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00523653

Contacts
Contact: Nadia S Giannetti, MD (514)934 1934 ext 32850 nadia.giannetti@much.mcgill.ca

Locations
Canada, Quebec
Royal Victoria Hospital Recruiting
Montreal, Quebec, Canada, H3A 1A1
Contact: Nadia Giannetti, MD       nadia.giannetti@muhc.mcgill.ca   
Sponsors and Collaborators
McGill University Health Center
Investigators
Principal Investigator: Nadia S Giannetti, MD McGill University Hospital Centre
Principal Investigator: Jamie Engert, PhD McGill University Health Center
  More Information

No publications provided

Responsible Party: Dr Nadia Giannetti, McGill University Health Center
ClinicalTrials.gov Identifier: NCT00523653     History of Changes
Other Study ID Numbers: BMB 07-004
Study First Received: August 29, 2007
Last Updated: March 17, 2008
Health Authority: Canada: Ethics Review Committee

Additional relevant MeSH terms:
Cardiomyopathy, Dilated
Cardiomyopathies
Cardiomegaly
Heart Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on April 21, 2014